Abstract
Metastasis of cancer cells involves multiple steps, including their dissociation from the primary tumor and invasion through the endothelial cell barrier to enter the circulation and finding their way to distant organ sites where they extravasate and establish metastatic lesions. Deficient contact inhibition is a hallmark of invasive cancer cells, yet surprisingly the vascular invasiveness of commonly studied cancer cell lines is regulated by the density at which cells are propagated in culture. Cells grown at high density were less effective at invading an endothelial monolayer than cells grown at low density. This phenotypic difference was also observed in a zebrafish model of vascular invasion of cancer cells after injection into the yolk sac and extravasation of cancer cells into tissues from the vasculature. The vascular invasive phenotypes were reversible. A kinome-wide RNA interference screen was used to identify drivers of vascular invasion by panning small hairpin RNA (shRNA) library-transduced noninvasive cancer cell populations on endothelial monolayers. The selection of invasive subpopulations showed enrichment of shRNAs targeting the large tumor suppressor 1 (LATS1) kinase that inhibits the activity of the transcriptional coactivator yes-associated protein (YAP) in the Hippo pathway. Depletion of LATS1 from noninvasive cancer cells restored the invasive phenotype. Complementary to this, inhibition or depletion of YAP inhibited invasion in vitro and in vivo. The vascular invasive phenotype was associated with a YAP-dependent upregulation of the cytokines IL6, IL8 and C-X-C motif ligand 1, 2 and 3. Antibody blockade of cytokine receptors inhibited invasion and confirmed that they are rate-limiting drivers that promote cancer cell vascular invasiveness and could provide therapeutic targets.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Fidler IJ . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453–458.
Nguyen DX, Bos PD, Massagué J . Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274–284.
Erez N, Coussens LM . Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer 2011; 128: 2536–2544.
Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M et al. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal 2011; 4: ra60.
Huh SJ, Liang S, Sharma A, Dong C, Robertson GP . Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res 2010; 70: 6071–6082.
Friedl P, Locker J, Sahai E, Segall JE . Classifying collective cancer cell invasion. Nat Cell Biol 2012; 14: 777–783.
Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70.
Zeng Q, Hong W . The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell 2008; 13: 188–192.
Tao W, Zhang S, Turenchalk GS, Stewart RA, St John MA, Chen W et al. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat Genet 1999; 21: 177–181.
St John MA, Tao W, Fei X, Fukumoto R, Carcangiu ML, Brownstein DG et al. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999; 21: 182–186.
Pan D . The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491–505.
Harvey KF, Zhang X, Thomas DM . The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246–257.
Mo J-S, Park HW, Guan K-L . The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep 2014; 15: 642–656.
Varelas X . The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 2014; vol. 141: pp 1614–1626.
Nance J . Cell biology in development: getting to know your neighbor: cell polarization in early embryos. J Cell Biol 2014; vol. 206: pp 823–832.
Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120–1133.
Piccolo S, Dupont S, Cordenonsi M . The Biology of YAP/TAZ: Hippo Signaling and Beyond. Physiol Rev 2014; vol. 94: pp 1287–1312.
Egeblad M, Nakasone ES, Werb Z . Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 2010; 18: 884–901.
Park HW, Guan K-L . Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci 2013; 34: 581–589.
Chen Q, Zhang N, Gray RS, Li H, Ewald AJ, Zahnow CA et al. A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis. Genes Dev 2014; 28: 432–437.
Lamar JM, Stern P, Liu H, Schindler JW, Jiang Z-G, Hynes RO . The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 2012; 109: E2441–E2450.
Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V et al. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol 2014; 134: 123–132.
Lau AN, Curtis SJ, Fillmore CM, Rowbotham SP, Mohseni M, Wagner DE et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J 2014; 33: 468–481.
Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G et al. Downstream of mutant KRAS, the transcription regulator YAP Is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sc Signal 2014; 7: ra42.
Greten FR . YAP1 takes over when oncogenic K-Ras slumbers. Cell 2014; 158: 11–12.
Bos PD, Zhang XH-F, Nadal C, Shu W, Gomis RR, Nguyen DX et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005–1009.
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537–549.
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518–524.
Stoletov K, Kato H, Zardouzian E, Kelber J, Yang J, Shattil S et al. Visualizing extravasation dynamics of metastatic tumor cells. J Cell Sci 2010; 123: 2332–2341.
Cross LM, Cook MA, Lin S, Chen J-N, Rubinstein AL . Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. Arterioscler Thromb Vasc Biol 2003; 23: 911–912.
Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee S-J, Anders RA et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26: 1300–1305.
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387–400.
Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211–215.
O'Connell JT, Sugimoto H, Cooke VG, Macdonald BA, Mehta AI, Lebleu VS et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA 2011; 108: 16002–16007.
Oehlers SHB, Flores MV, Hall CJ, O'Toole R, Swift S, Crosier KE et al. Expression of zebrafish cxcl8 (interleukin-8) and its receptors during development and in response to immune stimulation. Dev Comp Immunol 2010; 34: 352–359.
van der Aa LM, Chadzinska M, Tijhaar E, Boudinot P, Verburg-van Kemenade BML . CXCL8 chemokines in teleost fish: two lineages with distinct expression profiles during early phases of inflammation. PLoS One 2010; 5: e12384.
Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 2012; 18: 1511–1517.
Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N et al. Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor. Breast Cancer Res Treat 2012; 135: 79–91.
Bieche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L et al. CXC chemokines located in the 4q21 region are upregulated in breast cancer. Endocr Relat Cancer 2007; 14: 1039–1052.
Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150: 165–178.
Korkaya H, Kim G-I, Davis A, Malik F, Henry NL, Ithimakin S et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 2012; 47: 570–584.
Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23–35.
Rasanen K, Herlyn M . Paracrine signaling between carcinoma cells and mesenchymal stem cells generates cancer stem cell niche via epithelial-mesenchymal transition. Cancer Discov 2012; 2: 775–777.
Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH-F, Norton L et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315–1326.
Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C . IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. Cancer Res 2011; 71: 5296–5306.
Kim N-G, Koh E, Chen X, Gumbiner BM . E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci USA 2011; 108: 11930–11935.
Varelas X, Samavarchi-Tehrani P, Narimatsu M, Weiss A, Cockburn K, Larsen BG et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. Dev Cell 2010; 19: 831–844.
Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X et al. KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell 2014; 158: 171–184.
Oskarsson T, Acharyya S, Zhang XH-F, Vanharanta S, Tavazoie SF, Morris PG et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17: 867–874.
Melo SA, Kalluri R . miR-29b moulds the tumour microenvironment to repress metastasis. Nat Cell Biol 2013; 15: 139–140.
Stoletov K, Klemke R . Catch of the day: zebrafish as a human cancer model. Oncogene 2008; 27: 4509–4520.
Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR et al. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol 2009; 16: 712–723.
Al-Otaiby M, Tassi E, Schmidt MO, Chien CD, Baker T, Salas AG et al. Role of the Nuclear Receptor Coactivator AIB1/SRC-3 in Angiogenesis and Wound Healing. Am J Pathol 2012; 180: 1474–1484.
Tassi E, Mcdonnell K, Gibby KA, Tilan JU, Kim SE, Kodack DP et al. Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing. Am J Pathol 2011; 179: 2220–2232.
Oh A, List H-J, Reiter R, Mani A, Zhang Y, Gehan E et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res 2004; 64: 8299–8308.
Fereshteh MP, Tilli MT, Kim SE, Xu J, O'Malley BW, Wellstein A et al. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res 2008; 68: 3697–3706.
Acknowledgements
Dr Joan Massague kindly provided the MDA-MB-231 derivative cell lines used here. We thank Caroline E Laverriere for excellent assistance with the zebrafish experiments. Work was supported by NIH/NCI grant CA71508 (AW) and CA113477 (ATR) and CA51008 for zebrafish and mouse studies.
Author Contributions
GMS and AW designed the research and wrote the paper. GMS, MOS and EG performed the research. All authors discussed the results and commented on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Sharif, G., Schmidt, M., Yi, C. et al. Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling. Oncogene 34, 5879–5889 (2015). https://doi.org/10.1038/onc.2015.44
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.44
This article is cited by
-
Hsa_circ_0005273 facilitates breast cancer tumorigenesis by regulating YAP1-hippo signaling pathway
Journal of Experimental & Clinical Cancer Research (2021)
-
Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy
Science China Materials (2019)
-
A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
Scientific Reports (2017)
-
Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion
Oncogene (2017)
-
A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis
Nature Communications (2016)